Merz PR, et al. - Researchers gauged the potential cytotoxic impacts of two anti-vascular endothelial growth factor (VEGF) agents, ranibizumab (Lucentis) and bevacizumab (Avastin) on the human corneal endothelium. No cytotoxic effects on the corneal endothelium of human organ-cultured donor corneas over the limited study time period of 4 weeks were demonstrated by the anti-angiogenic agents ranibizumab (Lucentis) and bevacizumab (Avastin). Nonetheless, no conclusions on potential long-term effects can be drawn based on the study design (in-vitro) and the limited follow-up period.